Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has
been appointed to its board of directors. Dr. Chaplin formerly served as chief
scientific officer and head of research and development at OXiGENE, and more
recently has been a scientific advisor to the company. Dr. Chaplin has more
than 30 years in oncology research and drug development, and is known and
respected worldwide for his pioneering work in the field of vascular
disrupting technologies.

Commented Peter Langecker, M.D., Ph.D., President and Chief Executive Officer:
"Throughout his illustrious career in the biopharmaceutical industry, and
especially during his long and productive affiliation with OXiGENE, Dai has
earned international respect and admiration for his scientific acumen,
innovative thinking and executive leadership. OXiGENE has benefitted greatly
from his guidance and counsel in all aspects of our business. We believe that
as a newly appointed board member, Dai can now further contribute his
expertise to helping OXiGENE develop and implement strategies to strengthen
our ability to achieve our financing, clinical and corporate goals. The
OXiGENE management team and directors join me in welcoming Dai to the board,
and look forward to continuing our long and productive relationship."

Dr. Chaplin has been a leader in the field of vascular targeting and was the
original discoverer of the vascular disrupting action of Combretastatin
(ZYBRESTAT®). His original work formed the basis for not only the development
of ZYBRESTAT with OXiGENE, but also the subsequent vascular targeting
development programs at AstraZeneca and Aventis. Dr. Chaplin has more than 18
years of experience in oncology research. Prior to his association with
OXiGENE, Dr. Chaplin was Vice President, Oncology at Aventis Pharma in Paris.
Before the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell,
Dr. Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From
1992 to 1998, Dr. Chaplin led the Cancer Research Campaign's (CRC) Tumor
Microcirculation Group, based at the Gray Laboratory Cancer Research Trust,
Mount Vernon Hospital, London. Dr. Chaplin has also served as Section Head of
Cancer Biology at Xenova in the UK and has held a senior staff appointment at
the British Columbia Cancer Research Centre. Educated in the United Kingdom,
Dr. Chaplin has a B.Sc. in chemistry from the University of Essex, a M.Sc. in
pharmacology from the University of Southampton, and completed his Ph.D. in
tumor biology at the University of London.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents (VDAs) that selectively disrupt abnormal blood vessels
associated with solid tumor progression. OXiGENE is dedicated to leveraging
its intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release, which include the timing of
advancement, outcomes, and regulatory guidance relative to our clinical
programs, achievement of our business and financing objectives may turn out to
be wrong. Forward-looking statements can be affected by inaccurate assumptions
OXiGENE might make or by known or unknown risks and uncertainties, including,
but not limited to, the inherent risks of drug development and regulatory
review, and the availability of additional financing to continue development
of our programs.

Additional information concerning factors that could cause actual results to
materially differ from those in the forward-looking statements is contained in
OXiGENE's reports to the Securities and Exchange Commission, including
OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no
obligation to publicly update forward-looking statements, whether because of
new information, future events or otherwise. Please refer to our Annual Report
on Form 10-K for the fiscal year ended December 31, 2011.

CONTACT: Investor and Media Contact:
         ir@oxigene.com
         650-635-7000

company logo